CONCLUSION
HPO is a rare syndrome that could be idiopathic or secondary to
inflammatory, infectious or neoplastic cause. In this case HPO was a
paraneoplastic syndrome that revealed lung cancer. Clinicians should pay
close attention to physical complaints in schizophrenia because this
population is vulnerable to some somatic affections. Patients with
schizophrenia should be screened for lung cancer as soon as risk factors
are identified.
The major risk factor for lung cancer is tobacco consumption. In this
population the consumption is more important and more frequent. So, they
should imperatively be addressed to programs to quit smoking. For now,
we have anti-tobacco strategies that are addressed to the general
population. It would be more interesting and perhaps more effective to
elaborate strategies adapted to patients with schizophrenia.
1. Martínez-Lavín M. Hypertrophic osteoarthropathy. Best Pract Res Clin
Rheumatol. 1 juin 2020;34(3):101507.
2. Bonnot O, Anderson GM, Cohen D, Willer JC, Tordjman S. Are patients
with schizophrenia insensitive to pain? A reconsideration of the
question. Clin J Pain. avr 2009;25(3):244‑52.
3. Chakraborty RK, Sharma S. Secondary Hypertrophic Osteoarthropathy.
In: StatPearls [Internet]. Treasure Island (FL): StatPearls
Publishing; 2021 [cité 27 juin 2021]. Disponible sur:
http://www.ncbi.nlm.nih.gov/books/NBK513342/
4. Case records of the Massachusetts General Hospital. Weekly
clinicopathological exercises. Case 2-1997. A 38-year-old man with
digital clubbing, low-grade fever, and a murmur. N Engl J Med. 16 janv
1997;336(3):205‑10.
5. Catts VS, Catts SV, O’Toole BI, Frost ADJ. Cancer incidence in
patients with schizophrenia and their first-degree relatives - a
meta-analysis. Acta Psychiatr Scand. mai 2008;117(5):323‑36.
6. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lönnqvist J.
Incidence of cancer among persons with schizophrenia and their
relatives. Arch Gen Psychiatry. juin 2001;58(6):573‑8.
7. Bradford DW, Goulet J, Hunt M, Cunningham NC, Hoff R. A Cohort Study
of Mortality in Individuals With and Without Schizophrenia After
Diagnosis of Lung Cancer. J Clin Psychiatry. déc 2016;77(12):e1626‑30.
8. Fujiwara M, Inagaki M, Nakaya N, Fujimori M, Higuchi Y, Hayashibara
C, et al. Cancer screening participation in schizophrenic outpatients
and the influence of their functional disability on the screening rate:
A cross-sectional study in Japan. Psychiatry Clin Neurosci. déc
2017;71(12):813‑25.
9. Warren GW, Cummings KM. Tobacco and lung cancer: risks, trends, and
outcomes in patients with cancer. Am Soc Clin Oncol Educ Book Am Soc
Clin Oncol Annu Meet. 2013;359‑64.
10. Sagud M, Mihaljevic Peles A, Pivac N. Smoking in schizophrenia:
recent findings about an old problem. Curr Opin Psychiatry. sept
2019;32(5):402‑8.
11. Zuber V, Jönsson EG, Frei O, Witoelar A, Thompson WK, Schork AJ, et
al. Identification of shared genetic variants between schizophrenia and
lung cancer. Sci Rep. 12 janv 2018;8(1):674.
12. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation
and reduction in individuals with schizophrenia. Cochrane Database Syst
Rev. 28 févr 2013;(2):CD007253.
13. Pearsall R, Smith DJ, Geddes JR. Pharmacological and behavioural
interventions to promote smoking cessation in adults with schizophrenia
and bipolar disorders: a systematic review and meta-analysis of
randomised trials. BMJ Open. 28 nov 2019;9(11):e027389.